premature ejaculation/ドーパミン

BACKGROUND OF THE INVENTION Dopamine is a neurotransmitter found in various parts of the central nervous system. It is most prevalent in the substantia nigra (A9), the neostriatum, and the ventral tegmental area (A10). Dopamine binds to two general classes of receptors, termed D1- and D2-like

BACKGROUND OF THE INVENTION Dopamine is a neurotransmitter found in various parts of the central nervous system. It is most prevalent in the substantia nigra (A9), the neostriatum, and the ventral tegmental area (A10). Dopamine binds to two general classes of receptors, termed D1- and D2-like

BACKGROUND OF THE INVENTION Dopamine is a neurotransmitter found in various parts of the central nervous system. It is most prevalent in the substantia nigra (A9), the neostriatum, and the ventral tegmental area (A10). Dopamine binds to two general classes of receptors, termed D1- and D2-like

This application is a 371 of International Application No. PCT/EP2007/053115 filed 30 Mar. 2007, this application claims the priority of GB 0607896.8 filed 3 Apr. 2006 and GB 0703387.1 filed 21 Feb. 2007 which are incorporated herein in their entirety. The present invention relates to novel

This application is a 371 of International Application No. PCT/EP2007/054003 filed 24 Apr. 2007, this application claims the priority of GB 0608452.9 filed 27 Apr. 2006 and GB 0608457.8 filed 27 Apr. 2006 which are incorporated herein in their entirety. The present invention relates to novel

This application is a 371 of International Application No. PCT/EP2007/053117 filed 30 Mar. 2007, this application claims the priority of GB 0607892.7 filed 3 Apr. 2006 and GB 0703397.0 filed 21 Feb. 2007 which are incorporated herein in their entirety. The present invention relates to novel

This application is a 35 U.S.C. 371 application of International Application No. PCT/EP2006/003554, filed 12 Apr. 2006, and which claims the benefit of Provisional Application No. GB0507602.1, filed 14 Apr. 2005. The present invention relates to novel compounds, processes for their preparation,

This application is a 371 of International Application No. PCT/EP2008/063166, filed 1 Oct. 2008, which claims the benefit of GB 0719235.4, filed 2 Oct. 2007, which are incorporated herein in their entirety. The present invention relates to novel compounds, processes for their preparation,

The present invention relates to novel compounds, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D.sub.3 receptors. WO 2002/40471 (SmithKline Beecham) discloses certain

The present invention relates to novel compounds, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D.sub.3 receptors. WO 2002/40471 (SmithKline Beecham) discloses certain

This application is a 35 U.S.C. 371 application of International Application No. PCT/EP2006/005767, filed 13 Jun. 2006, and which claims the benefit of Provisional Application No. GB0604897.9, filed 14 Jun. 2005. The present invention relates to novel compounds, processes for their preparation,

The present invention relates to novel compounds, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D.sub.3 receptors. WO 2002/40471 (SmithKline Beecham) discloses certain

This application is a 35 U.S.C. 371 application of International Application No. PCT/EP2006/003778, filed 13 Apr. 2006, and which claims the benefit of Provisional Application No. GB0507680.7, filed 15 Apr. 2005. The present invention relates to novel compounds, processes for their preparation,

The present invention relates to novel compounds, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D.sub.3 receptors. WO 2002/40471 (SmithKline Beecham) discloses certain

The present invention relates to novel compounds, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D.sub.3 receptors. WO 2002/40471 (SmithKline Beecham) discloses certain